You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 和黃醫藥(0013.HK)低開5.38% 2021年虧損擴大
格隆匯 03-04 09:28
格隆匯3月4日丨和黃醫藥(0013.HK)低開5.38%,報39.6港元,總市值342億港元。該公司昨日發佈公吿,2021年總收入增長56%至3.561億美元,受三款自主研發腫瘤藥物愛優特、蘇泰達及沃瑞沙的商業化進展所推動;2021年和黃醫藥應占淨虧損為1.946億美元,每股虧損25美分,超市場預期的18美分,而2020年為1.257億美元。該公司表示,首席執行官賀雋將退休。賀雋已於公司工作近二十二年(包括擔任執行董事及首席執行官職務十五年);及委任蘇慰國為公司新任首席執行官。蘇慰國博士已於公司工作約十七年(包括擔任首席科學官約十年及執行董事職務近五年)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account